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ABSTRACT
Background. Complement dysregulation occurs in thrombotic
microangiopathies (TMAs) other than primary atypical haemo-
lytic uraemic syndrome (aHUS). A few of these patients have been
reported previously to be successfully treated with eculizumab.
Methods. We identiﬁed 29 patients with so-called secondary
aHUS who had received eculizumab at 11 Spanish nephrology
centres. Primary outcome was TMA resolution, deﬁned by a
normalization of platelet count (>150  109/L) and haemoglo-
bin, disappearance of all the markers of microangiopathic
haemolytic anaemia (MAHA), and improvement of renal func-
tion, with a25% reduction of serum creatinine from the onset
of eculizumab administration.
Results. Twenty-nine patients with secondary aHUS (15 drug-
induced, 8 associated with systemic diseases, 2 with postpartum,
2 with cancer-related, 1 associated with acute humoral rejection
and 1 with intestinal lymphangiectasia) were included in this
study. The reason to initiate eculizumab treatment was worsen-
ing of renal function and persistence of TMA despite treatment
of the TMA cause and plasmapheresis. All patients showed
severe MAHA and renal function impairment (14 requiring dia-
lysis) prior to eculizumab treatment and 11 presented severe
extrarenal manifestations. A rapid resolution of the TMA was
observed in 20 patients (68%), 15 of them showing a50%
serum creatinine reduction at the last follow-up. Comprehensive
genetic and molecular studies in 22 patients identiﬁed comple-
ment pathogenic variants in only 2 patients. With these two
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|exceptions, eculizumab was discontinued, after a median of
8 weeks of treatment, without the occurrence of aHUS relapses.
Conclusion. Short treatment with eculizumab can result in a
rapid improvement of patients with secondary aHUS in whom
TMA has persisted and renal function worsened despite treat-
ment of the TMA-inducing condition.
Keywords: atypical haemolytic uraemic syndrome, comple-
ment activation, eculizumab, thrombotic microangiopathies
INTRODUCTION
Thrombotic microangiopathies (TMAs) is a group of devas-
tating diseases with very different aetiologies that share com-
mon characteristic features at presentation: microangiopathic
haemolytic anaemia (MAHA) [typified by anaemia, elevated
lactate dehydrogenase (LDH), decreased serum haptoglobin
and the presence of schistocytes in peripheral blood smear],
thrombocytopenia and organ damage, mainly the kidneys and
the nervous system. The pathogenesis of TMA is based on a
diffuse and severe vascular endothelial injury inducing charac-
teristic histological lesions in affected organs: platelet throm-
bus occluding vessels, swelling and detachment of endothelial
cells, and thickening of arterioles and capillaries [1–5].
The most widely accepted classification establishes four cate-
gories of TMA: Shiga toxin-producing Escherichia coli haemolytic
uraemic syndrome (STEC-HUS), thrombotic thrombocytopenic
purpura (TTP), atypical haemolytic uraemic syndrome (aHUS)
and secondary TMA [1–5]. This last group includes a long list of
clinical entities in which the occurrence of TMA has been repeat-
edly reported: drug treatments [6, 7], systemic diseases [8–10],
pregnancy/postpartum [11, 12], cancer [7, 13], haematopoietic
stem cell and organ transplantation [14, 15], systemic infections
[16, 17], glomerular diseases [18, 19], malignant hypertension
[20] and some very rare conditions such as intestinal lymphan-
giectasia [21] or methylmalonicaciduria [22]. The pathogenesis of
STEC-HUS, TTP and aHUS has been largely clarified in recent
years [1–5], but the pathogenic pathways through which endo-
thelial damage is induced in secondary TMA are not completely
elucidated. It is generally accepted that in a significant number of
patients within the group of secondary TMA there is a
complement-related damage to the endothelium.
Eculizumab is a humanized monoclonal antibody that binds
to complement C5 and prevents the formation of C5b-9, the
membrane attack complex of the terminal complement path-
way [23]. The efficacy and safety of eculizumab in aHUS has
been demonstrated by observational studies and prospective
multicentre trials [23, 24].
Complement is a tightly controlled part of our innate immun-
ity, fundamental among other things for the elimination of
pathogens and cellular debris generated by normal tissue homeo-
stasis. aHUS caused by pathogenic variants in the genes coding
for complement components and regulators, or by autoantibod-
ies against these proteins [1–5, 25, 26], is referred here as primary
aHUS, as suggested in the KDIGO Controversies Conference on
aHUS and C3G [27]. The genetic and acquired factors associated
with primary aHUS cause complement dysregulation resulting
in damage to the endothelial cells in the microvasculature of the
kidneys and other organs. While complement dysregulation is
central to the pathogenesis of primary aHUS, cumulative evi-
dence suggests that complement hyperactivation and dysregula-
tion also occurs in other forms of TMA apart from primary
aHUS, including some patients with STEC-HUS and TTP, and
may be particularly relevant in an important number of second-
ary TMA cases (reviewed in [28]). We will refer to these cases of
TMA as secondary aHUS. Further supporting the involvement
of complement dysregulation in other forms of TMA apart from
primary aHUS, individual case reports and small series of pa-
tients have been published in recent years showing a beneficial
effect of eculizumab in cases of TMA associated with haemato-
poietic stem cell transplantation [29, 30], antiphospholipid syn-
drome [31, 32], systemic diseases [33, 34], pregnancy/
postpartum [35] and drug treatments [36–38]. However, the
small number of reported cases and the well-known tendency to
preferentially publish those cases responding positively to new
therapies prevents the generalization of such positive results.
To assess the potential benefit of eculizumab in this, so-called,
secondary aHUS, we designed a collaborative retrospective study
to identify these cases and revise those who had received eculizu-
mab, independently of the aetiological factor causing the TMA
and the final outcome of the eculizumab treatment.
MATERIALS AND METHODS
Study population and treatment
Patients with secondary aHUS treated with eculizumab were
identified in 11 Spanish hospitals. Inclusion criteria were: (i) evi-
dence of TMA, defined by the presence of low platelet count
(<150 109/L), MAHA (low haemoglobin, LDH level above the
upper limit of the normal range, decreased serum haptoglobin
and presence of schistocytes in peripheral blood examination),
negative Coombs test, normal activity of ADAMTS-13, negative
Shiga toxin and impaired renal function fulfilling the criteria of
acute kidney injury (AKI) [39]; (ii) diagnosis of secondary TMA,
based on the presence of a precipitating cause listed among the
recognized aetiologies of secondary TMA [5]; (iii) persistence of
TMA and worsening of renal function despite the treatment of
the TMA-precipitating trigger or disease; and (iv) treatment with
eculizumab after previous treatments had failed. Exclusion crite-
ria included previous episodes of TMA and, in renal transplant
patients, the diagnosis of aHUS or C3 glomerulopathies in native
kidneys. Patients fulfilling these inclusion and exclusion criteria
were included in the study, independently of the TMA cause and
patient’s outcome after eculizumab treatment.
Eculizumab was administered in all the patients intraven-
ously at a dose of 900mg/week for 4 weeks, and then 1200mg
every 2 weeks. Plasmapheresis was discontinued in all the pa-
tients once they started eculizumab. All the patients received
anti-meningococcal vaccination, according to label instructions,
and received antibiotic prophylaxis. The duration of eculizumab
therapy was decided by the treating physician, based on the pa-
tient’s response and individual characteristics. Baseline data
were considered to be the data coinciding with the detection of
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TMA. Follow-up was defined as the interval between the onset
of eculizumab and the last visit or death.
Data collection
Data were compiled from the medical records of the partici-
pating centres using a uniform protocol and included age, gen-
der, blood pressure and cause of TMA. Analytical variables
included haemoglobin, platelet count, haptoglobin, LDH, pres-
ence of schistocytes in peripheral blood smear, Coombs test,
ADAMTS-13 determination, Shiga toxin detection, serum cre-
atinine (SCr), estimated glomerular filtration rate (eGFR),
which was calculated using the four-variable Modification of
Diet in Renal Disease equation, serum albumin and urinalysis.
Results of the genetic analysis, performed in 22 patients were
registered following a common protocol.
Treatments received before eculizumab, number of plasma-
pheresis sessions and the time interval between TMA onset and
the initiation of eculizumab treatment were recorded, as well as
the duration of eculizumab therapy and the cumulative dose ad-
ministered to every patient. Complications occurring during
plasmapheresis and eculizumab treatment, side effects, the occur-
rence of end-stage renal disease and deaths were also recorded.
Renal biopsies were performed in 18 patients and were re-
viewed for this study at every participating centre. Histological
signs of TMA included glomerular and arteriolar thrombus,
thickening of arteriolar walls, swelling and detachment of endo-
thelial cells, widening of subendothelial space in glomerular
capillaries and glomerular retraction.
Outcomes
The primary outcome was TMA resolution, defined by a
normalization of platelet count (>150  109/L), normalization
of haemoglobin, disappearance of all the markers of MAHA
and recovery of renal function, with a25% reduction in SCr in
two consecutive measurements for4 weeks from the onset of
eculizumab administration. Secondary outcomes were the nor-
malization of platelet count and haemoglobin with the dis-
appearance of MAHA markers, the number of patients
requiring dialysis, a25% and a50% reduction from the
onset of eculizumab in SCr and the number of patients with an
eGFR60mL/min/1.73 m2 at latest follow-up.
Statistical analysis
Continuous variables were expressed as median and inter-
quartile (25th and 75th percentile) range. Categorical variables
were expressed as frequencies and percentages. Categorical vari-
ables were compared with the Fisher’s exact probability test and
the medians were compared using the Mann–Whitney U test.
To compare more than two categorical variables, the chi-square
(v2) test was used. Statistical analyses were performed with
STATA software for Windows, version 12.0 (Statacorp LP,
College Station, TX, USA) with two-sided hypothesis testing
and a P< 0.05 as the criteria for statistical significance.
Other methods
Complement genetic and molecular studies are described in
detail in Supplementary Methods.
RESULTS
Clinical characteristics
Twenty-nine patients were included in the study. Their main
clinical characteristics at the onset of eculizumab treatment are
summarized in Tables 1–4. MAHA and AKI were evident in all
patients. Normal ADAMTS-13 activity was assessed in all pa-
tients, with a median value of 68% (60–78%). Stool analysis for
Shiga toxin detection and Coombs test, performed in 14 and 24
patients, respectively, were negative. Fourteen patients (48%)
were undergoing dialysis at the onset of eculizumab due to the
severity of renal failure and/or volume expansion. Severe extra-
renal manifestations were observed in 11 patients (38%): five
patients presented with seizures, three had decreased level of
consciousness, four headache and blurred vision, and one had
dilated cardiomyopathy.
Causes of aHUS and treatment before eculizumab
As shown in Table 1, aHUS was induced by drugs in 15 pa-
tients, by systemic diseases in 8, by postpartum in 2, by cancer
in 2, by acute humoral rejection in 1 and by primary intestinal
lymphangiectasia in 1. All drug-induced aHUS corresponded to
transplanted patients who had received a kidney graft (seven
patients), lung (four patients), haematopoietic stem cells (two
Table 1. Characteristics at the initiation of eculizumab treatment
Patients (n ¼ 29)
Age (years)a 51.8 (36.2–59.6)
Gender, no. (%), male 16 (55.2)
Cause of aHUS, no. (%)
Drug-induced 15 (51.7)
Tacrolimus 14 (93.3)
Everolimus 4 (26.7)
Sirolimus 1 (6.7)
Systemic disease 8 (27.6)
SLE 3 (37.5)
Scleroderma 2 (25)
Vasculitis (EGPA) 2 (25)
Antiphospholipid syndrome 1 (12.5)
Other causes 6 (20.7)
Pregnancy/postpartum 2 (33.3)
Cancer related 2 (33.3)
Acute humoral rejection renal transplant 1 (16.7)
Primary intestinal lymphangiectasia 1 (16.7)
Time from aHUS diagnosis to
eculizumab treatment (days)
13 (7–26)
Extrarenal manifestation, no. (%) 11 (37.9)
Dialysis before eculizumab, no. (%) 14 (48.3)
Laboratory ﬁndings
SCr (mg/dL)a 4 (3.4–5.6)
eGFR (mL/min/1.73 m2)a 13 (7.7–19.0)
LDH (mg/dL)a 960 (570–1950)
Haptoglobin (mg/dL)a 5 (0–12)
Haemoglobin (g/dL)a 8.8 (8.1–9.9)
Platelet count (1000/mL)a 73 (51–113)
Schystocites, no. (%) 28 (96.6)
Follow-up (months)a 5.2 (4.2–14.1)
eGFR, estimated glomerular ﬁltration rate; EGPA, eosinophilic granulomatosis with pol-
yangiitis; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome; LDH,
lactate dehydrogenase.
aMedian (25th–75th percentile).||
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||patients), liver (one patient) or heart (one patient) (Table 2). In
seven patients with a kidney graft (#1 to #7), median interval be-
tween transplantation and aHUS detection was 14 days (7–20).
Induction treatment consisted of corticosteroids, tacrolimus
and mycophenolate mofetil in all of them. Four patients (#1, #2,
#3 and #6) also received antithymocyte globulin.
The offending drug was tacrolimus (combined with everoli-
mus in patients #9, #10 and #11 and with sirolimus in patient
#13, Table 2) in all but one patient (Table 2), in whom aHUS
was attributed to everolimus (patient #7). Offending drugs were
discontinued in all the patients but one (patient #3), without
TMA improvement (Table 2). In this patient (hyperimmunized
recipient of a second transplant), tacrolimus was maintained
due to the high risk of rejection.
Eculizumab was initiated after only two to three sessions of
plasmapheresis in patients #1, #3, #4 and #12 with drug-
induced aHUS (Table 2) due to the progressive deterioration in
these cases of renal function and the persistence of severe extra-
renal manifestations (seizures, blurred vision, decreased level of
consciousness), as well as the appearance of plasmapheresis-
related complications, transfusion-related reaction and bleeding
in patients #4 and #12.
Systemic disease-related aHUS occurred in eight patients:
systemic lupus erythematosus (SLE) in three, systemic sclero-
derma in two, eosinophilic granulomatosis with polyangiitis
(EGPA) in two and primary antiphospholipid syndrome in one
(Table 3). All the patients with systemic diseases developed
aHUS in their native kidneys, with the exception of the patient
with primary antiphospholipid syndrome, who presented
aHUS 7 days after renal transplantation. In four out of eight pa-
tients (50%), aHUS was the first manifestation of the disease
(patients #16, #17, #19 and #20). Patients with systemic diseases
received different types of immunosuppressive treatments be-
fore eculizumab (Table 3).
Six patients presented a miscellany of secondary TMA
causes: aHUS appearing after delivery in two patients, cancer-
related aHUS in two (metastatic prostate cancer in both), aHUS
associated with acute humoral rejection in a kidney transplant
patient and with primary intestinal lymphangiectasia in another
patient (Table 4). Antiandrogenic therapy, immunosuppressive
anti-rejection treatments and antibiotics have been prescribed
for prostate cancer, humoral rejection and intestinal lymphan-
giectasia, respectively.
Plasmapheresis was performed before the onset of eculizu-
mab in 24 patients (83%), 13 with drug-induced aHUS, 5 with
systemic diseases, 2 with postpartum aHUS, 2 with cancer-
related aHUS, 1 with acute humoral rejection and 1 with pri-
mary intestinal lymphangiectasia (Tables 2–4). Complications
related to the performance of plasmapheresis were transfusion-
related reactions (five), deep vein thrombosis (two), bleeding
(one) and hypotension (one).
Renal biopsies
Renal biopsies were performed in 18 patients (62%).
Characteristic lesions of TMAwere found in all of them. A renal
biopsy was performed in six out of seven kidney transplant pa-
tients with drug-induced aHUS (patients #2, #3, #4, #5, #6 and
#7). No lesions of antibody-mediated rejection (AMR) were
found and C4d staining was negative in all of them. C3 glomer-
ulopathy was diagnosed in patient #11, on the basis of strong,
isolated deposits of C3 in immunofluorescence studies. A mem-
branoproliferative glomerulonephritis likely associated with
hepatitis C virus infection was found in patient #14 (Table 2).
Among patients with aHUS associated with systemic diseases, a
Table 2. Drug-induced aHUS
Patient Age (years),
gender
Offending drug Treatment before
eculizumab
PE no. of
sessions
Eculizumab
(duration,
no. of doses)
Time from
aHUS to
eculizumab
(days)
Highest SCr
(mg/dL) HD
(Yes/No)
Latest SCr
(mg/dL)
Follow-up
(months)
1 43, female Tacrolimusa DW þ PE 3 2 weeks, 2 4 3.8 No 1.1 16.2
2 63 female Tacrolimusa DW þ PE 10 18 weeks, 11 53 3.1 Yes 2.0 5.9
3 34, male Tacrolimusa PE 3 24 weeks, 14 10 9.8 Yes 2.6 6.7
4 18, female Tacrolimusa DW þ PE 2 3 weeks, 3 14 2.1 No 2 9.6
5 52, female Tacrolimusa DW – 8 weeks, 6 26 2.9 No 1.2 8.3
6 43, male Tacrolimusa DW þ PE 6 30 weeks, 17 35 3.8 Yes 1.1 16.2
7 36, female Everolimusa DW þ PE 6 6 weeks, 5 9 4.2 No 2.1 17.5
8 60, male Tacrolimusb DW – 4 weeks, 4 53 3.4 Yes 2.5 3.4
9 67, male Tacrolimus, everolimusb DW þ PE 6 6 weeks, 5 10 1.8 No 2.0 1.7
10 59, male Tacrolimus, everolimusb DW þ PE 5 10 weeks, 7 7 3.5 No 2.0 4.8
11 65, male Tacrolimus, everolimusb DW þ PE 6 2 weeks, 2 9 3.3 No 2.4 4.5
12 51, male Tacrolimusc DW þ PE 2 4 weeks, 4 10 2.4 No 0.6 2.9
13 54, female Tacrolimus, sirolimusc DW þ PE 7 3 weeks, 3 7 4.2 Yes 1.2 1.5
14 55, male Tacrolimusd DW þ PE 12 18 weeks, 11 27 3.0 No 2.4 14.1
15 42, female Tacrolimuse DW þ PE 3 3 weeks, 3 13 1.4 No 0.5 17.0
DW, drug withdrawn; HD, haemodialysis (Yes/No); PE, plasma exchange; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.
aKidney transplant.
bLung transplant.
cHaematopoietic stem cell transplantation.
dLiver transplant.
eHeart transplant.
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|class IV-S (C) lupus nephritis with advanced glomerular and
interstitial sclerosing lesions was found in two patients with SLE
(patients #16 and #17, Table 3) and a class IV-G (A) lupus
nephritis in the remaining SLE patient (patient #18, Table 3).
Patients with EGPA showed histological signs of vasculitis
(fibrinoid necrosis in glomerular capillaries and arterioles with
eosinophilic granulomas and interstitial infiltration by eosino-
phils) in addition to TMA. Renal biopsy in patient #24, with
postpartum aHUS, showed characteristic lesions of TMA with
no tubular necrosis. Renal biopsy in the patient with acute hu-
moral rejection-induced aHUS showed histological signs of
acute humoral rejection (tubulitis, arteritis, C4d-positive stain-
ing) in addition to TMA.
Eculizumab treatment
Eculizumab was started 13 (7–26) days after the onset of
aHUS. In two patients (#22 and #29, Tables 2–4), investigators
decided to maintain eculizumab after TMA resolution due to
the identification of complement pathogenic variants in CFH
and CFHR1 (see ‘Complement genetic studies’ section). In 27
remaining patients, eculizumab was discontinued after 8 (3–18)
weeks. The average number of eculizumab doses in these 27 pa-
tients was 6 (3–11).
Outcomes
A rapid improvement in haematological and renal abnor-
malities after the onset of eculizumab was observed in 20 pa-
tients (69%) (Table 5 and Figure 1). The rate of response varied
according to the aetiology of aHUS: 12/15 (80%) among drug-
induced aHUS, 6/6 (100%) in postpartum, cancer-related, acute
humoral rejection and intestinal lymphangiectasia, and 2/8
(25%) in aHUS associated with systemic diseases (Table 6).
Among the latter, only one patient with EGPA and the patient
with primary antiphospholipid syndrome showed TMA reso-
lution after eculizumab treatment (Tables 2–4). The interval be-
tween eculizumab initiation and TMA resolution averaged 12
(7–17) days. All extrarenal manifestations showed a rapid and
dramatic improvement.
Resolution of haematological abnormalities with no im-
provement in renal function was observed in six patients (pa-
tients #4, #9, #17, #18, #20 and #22). In three cases (patients
#8, #16 and #19), both haematological abnormalities and
renal function impairment persisted despite eculizumab
treatment (Tables 2–4).
At the last follow-up, the number of patients requiring dia-
lysis had decreased to 4 (13%), a25% decrease in SCr was
observed in 20 patients (69%), a50% decrease in 15 (52%)
and 10 patients (35%) had achieved an eGFR60mL/min/
1.73 m2.
Table 4. Other causes of secondary aHUS
Patient Age (years),
gender
TMA cause Treatment before
eculizumab
PE no. of
sessions
Eculizumab
(duration,
no. of doses)
Time from
aHUS to
eculizumab
(days)
Highest SCr
(mg/dL) HD
(Yes/No)
Latest SCr
(mg/dL)
Follow-up
(months)
24 27, female Postpartum PE 15 46 weeks, 25 24 4.1 No 1.5 13
25 35, female Postpartum PE 8 16 weeks, 10 17 5.9 Yes 1.2 4.2
26 61, male Cancer-related aHUSa Bilateral orchiectomy þ PE 2 10 weeks, 7 3 11.1 Yes 0.9 5.2
27 73, male Cancer-related aHUSa Antiandrogentherapy þ PE 4 81 weeks, 43 4 8.7 Yes 1.0 22.6
28 35, male Acute humoral rejection CS þ IVIg þ Rtx þ PE 5 3 weeks, 3 7 4.9 No 1.6 10.7
29 13, female Primary intestinal
lymphangiectasia
PE 4 64 weeks,
ongoing
21 5.4 Yes 0.3 16.4
CS, corticosteroids; HD, haemodialysis; IVIg, intravenous immunoglobulin; PE, plasma exchange; Rtx, rituximab; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.
aCancer-related aHUS:metastatic prostate cancer.
Table 3. aHUS associated with systemic disease
Patient Age (years),
gender
Systemic
disease
Treatment before
eculizumab
PE no. of
sessions
Eculizumab
(duration,
no. of doses)
Time from
aHUS to
eculizumab
(days)
Highest SCr
(mg/dL) HD
(Yes/No)
Latest SCr
(mg/dL)
Follow-up
(months)
16 51, female SLEa CS þ Cyc þ Rtx þ PE 10 4 weeks, 4 31 4.2 Yes Dialysis 0.9
17 16, female SLEa CS þMMF – 10 weeks, 7 1 7.1 Yes Dialysis 4.2
18 52, female SLE CS þ Cyc þ PE 27 2 weeks, 2 38 6.4 Yes 4.2 4.0
19 63, male Scleroderma CS þ Cyc þ PE 10 6 weeks, 5 55 4.9 No Dialysis 12.9
20 56, male Scleroderma CS þMtx þ PE 10 8 weeks, 6 25 3.7 No 3.4 4.3
21 52, male EGPA CS þ Cyc – 16 weeks, 10 5 3.5 No 2.3 4.3
22 49, male EGPA CS þ Cyc þ PE 2 130 weeks, ongoing 15 6.5 Yes Dialysis 29.5
23 38, male Primary APS – – 14 weeks, 9 1 9.5 Yes 3.4 4.4
aaHUS, atypical haemolytic uraemic syndrome; APS, Antiphospholip syndrome; CS, corticosteroids; Cyc, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; HD,
Hemodialysis (Yes/No); Mtx, methotrexate; MMF, mycophenolate mofetil; ND, not done; PE, plasma exchange; Rtx, rituximab; SCr, serum creatinine; SLE, systemic lupus erythematosus.
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No differences in baseline characteristics were observed be-
tween responder and non-responder patients, but there was a
significantly higher number of patients with aHUS associated
with systemic diseases among non-responders. Interestingly,
the duration of eculizumab treatment was significantly longer
in responder patients and there was a non-significant trend
towards a longer interval between aHUS diagnosis and onset of
eculizumab in non-responder patients (Table 7).
Complement genetic studies
Comprehensive complement studies were performed in
22/29 patients (Supplementary Table). These include western
blot analyses and quantification of components, search for anti-
Factor H (FH) autoantibodies and genetic screenings to identify
pathogenic variants and copy number variations. Only two pa-
tients carry pathogenic variants. Patient #22, affected by EGPA,
carries two pathogenic changes in CFHR1 (L290S and A296V)
resulting in a mutant FHR-1 protein that competes with FH
regulation on endothelial surfaces, and patient #29, affected by
intestinal lymphangiectasia, who presents a pathogenic variant
in CFH (C597*) that results in a partial FH deficiency. Patients
#11 and #12 carry anti-FH autoantibodies, but presented nor-
mal C3 levels and do not have the CFHR3–CFHR1 deletion,
suggesting that these anti-FH autoantibodies may not be func-
tionally relevant in the context of aHUS. Finally, some patients
carry genetic variants in complement genes with unknown
functional significance that were considered non-pathogenic.
Safety
Eculizumab was well tolerated. Serious infections occurred
in two transplanted patients during eculizumab administration
(prostatic abscess in one, herpes zoster infection in the other)
but they were likely related to immunosuppressive treatment
and resolved with appropriate treatments.
DISCUSSION
Our study shows that eculizumab is an effective treatment for
severe cases of secondary aHUS. In 20/29 eculizumab-treated
patients (69%), there was a normalization of haemoglobin and
platelet count together with a renal function improvement of at
least a25% reduction in SCr from the onset of eculizumab
treatment. Renal function recovery was remarkable, allowing
the discontinuation of dialysis in 10/14 patients. A de-
crease50% in SCr was observed in 15 patients, and 10 patients
(35%) showed an eGFR60mL/min/1.73 m2 at the last follow-
up. Eculizumab has been reported to be beneficial in individual
cases or small series of secondary TMA [29–38], haematopoietic
stem cell transplantation-induced aHUS being the entity in
which the effects of eculizumab treatment have been more ex-
tensively documented [29, 30]. Our study is the first to confirm
Table 5. Changes from baseline in haematological parameters and renal function
Baseline Eculizumab onset 4 weeks 12 weeks Last follow-up
Platelet count (1000/mL)a 65 (45–109) 73 (51–113) 166 (142–219) 202 (157–254) 182 (163–237)
Haemoglobin (g/dL)a 8.7 (7.8–10.4) 8.8 (8.1–9.9) 10.5 (10–11.1) 11 (10.2–12.3) 11.8 (10.2–12.4)
Haptoglobin (mg/dL)a 5 (0–5) 5 (0–12) 69 (32–115) 118 (88–141) 116 (86–135)
Serum creatinine (mg/dL)a 3.5 (2.7–5.2) 4.0 (3.4–5.6) 2.3 (1.1–3.9) 2.1 (1.1–3.5) 2.0 (1.1–2.6)
eGFR (mL/min/1.73 m2)a 18 (8.9–26) 13 (7.7–19) 27 (17–54) 32 (26–71) 34 (28–63)
eGFR, glomerular ﬁltrate rate.
aMedian (25th–75th percentile).
FIGURE 1: Changes in (A) serum creatinine, (B) haemoglobin and
(C) platelet count.
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|these positive effects in a relatively large series of secondary
aHUS patients.
TMA responses after eculizumab treatment were particularly
remarkable in patients with drug-induced aHUS (80% of TMA
resolution) and in a miscellaneous group of secondary aHUS
that included postpartum, cancer, acute humoral rejection and
intestinal lymphangiectasia (100%). Although many patients
with drug-induced aHUS show a rapid resolution after with-
drawal of the offending drug, TMA can persist in others, requir-
ing additional therapeutic measures because of life-threatening
organ involvement or progressive renal impairment [7, 40].
Plasmapheresis, immunosuppression and, in a few patients,
eculizumab [36–38] have been tried in these resistant cases. Our
results confirm that eculizumab is very effective to rapidly re-
solve TMA and improve renal function in this type of resistant
drug-induced secondary aHUS.
Tacrolimus was the most common offending drug among
our patients with drug-induced aHUS. Although tacrolimus dis-
continuation likely collaborated in TMA resolution, the rapid
and dramatic improvement associated with eculizumab adminis-
tration suggests a direct effect of complement blockade in TMA
response in these patients. On the other hand, AMR in renal
transplant patients can present features of TMA in renal biopsies
and some reports have suggested a beneficial effect of eculizumab
in AMR [41]. However, no lesions of AMR were observed in the
renal biopsies of our kidney transplant patients with drug-
induced aHUS and C4d staining was negative in all of them.
On the contrary, our results show limited benefit of eculizu-
mab administration in patients with systemic diseases (25% of
TMA responses). Only one patient with primary antiphospholi-
pid syndrome and another with ANCA vasculitis responded to
eculizumab, whereas patients with SLE (three), scleroderma
(two) and ANCA vasculitis (one) did not. These data do not
agree with the eculizumab benefits reported in anecdotic cases
of scleroderma-like syndrome and lupus nephritis complicated
with aHUS [33, 34], but it should be stressed that our patients
with SLE, scleroderma and ANCA vasculitis presented severe
lesions in their renal biopsies at the initiation of eculizumab
treatment.
Patients included in the study were treated according with
the condition triggering TMA (discontinuation of the offending
drug in drug-induced cases, immunosuppressive therapy in sys-
temic diseases and humoral rejection, antitumoral treatment in
cancer-related cases), and plasmapheresis was performed in
24 patients (83%) before initiation of eculizumab treatment.
Despite these measures, renal function continued to deteriorate
in all the patients and, at the time of eculizumab initiation,
14 patients (48%) were requiring dialysis. Persistent severe an-
aemia and thrombocytopenia was present in all patients
(Table 1). Eculizumab rapidly resulted in the responder patients
Table 6. Outcomes
Baseline Eculizumab onset 4 weeks 12 weeks Last follow-up
TMA response, no. (%)
Total 0 (0) 0 (0) 11 (37.9) 19 (65.5) 20 (68.9)
Related to drugs 0 (0) 0 (0) 6 (40) 12 (80) 12 (80)
Related to systemic disease 0 (0) 0 (0) 1 (12.5) 1 (12.5) 2 (25)
Related to other causes 0 (0) 0 (0) 4 (66.7) 6 (100) 6 (100)
Patients undergoing dialysis, no. (%) 4 (13.8) 14 (48.3) 4 (13.8) 4 (13.8) 4 (13.8)
Patients with 50% decrease from baseline SCr, no. (%) 0 (0) 0 (0) 10 (34.5) 14 (48.3) 15 (51.7)
Patients with eGFR 60mL/min/1.73 m2 0 (0) 0 (0) 6 (20.7) 10 (34.5) 10 (34.5)
TMA, thrombotic microangiopathy; eGFR, glomerular ﬁltrate rate; SCr, serum creatinine.
Table 7. Differences between responder and non-responder patients
Responders (n ¼ 20) Non-responders (n ¼ 9) P
Age (years)a 47.4 (35.9–57.5) 51.9 (49.9–60.1) 0.57
Gender, no. (%), male 11 (55.0) 5 (55.6) 1
Baseline SCr (mg/dL)a 3.4 (2.8–4.5) 3.4 (1.8–6.2) 0.75
SCr at the onset of Eculizumab (mg/dL)a,b 3.8 (3.2–5.4) 4.5 (3.4–6.7) 0.82
Dialysis, no. (%)b 9 (45) 5 (55.6) 0.70
Haemoglobin (g/dL)a,b 9.0 (8.1–10) 8.3 (7.7–104) 0.65
Platelet count (1000/mL)a,b 78 (51–138) 61 (29–80) 0.25
Cause of aHUS, no. (%) 0.004
Systemic disease 2 (25) 6 (75)
Drug induced 12 (80) 3 (20)
Other causes 6 (100) 0 (0)
Plasma exchange, no. (%) 17 (85) 7 (77.8) 0.50
Time between aHUS and eculizumab (days)a 9.5 (6–22.5) 25 (14–38) 0.059
Eculizumab duration (weeks)a 11.6 (4–24.7) 4.4 (3–8.4) 0.003
SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.
aMedian (25th–75th percentile).
bAt the onset of eculizumab.
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|(20/29) in an improvement of renal function and the disappear-
ance of all haematological abnormalities (Table 5 and Figure 1).
Among the non-responders, the haematological abnormalities
disappeared with eculizumab in 6/9 patients, although none of
them showed a substantial renal function recovery. Extrarenal
manifestations showed a rapid resolution after eculizumab initi-
ation. Particularly dramatic was the rapid disappearance of life-
threatening neurological complications (seizures, coma) in pa-
tients #12, #13, #15, #19, #20 and #22.
Complement is activated in several types of TMA other than
primary aHUS [28]. In STEC-HUS, Shiga toxin upregulates the
membrane adhesion molecule P-selectin, which binds C3b and
activates the complement alternative pathway (AP) [42, 43]. Low
C3 and increased sC5b-9 have been reported in most severe cases
of STEC-HUS [44, 45]. In TTP, levels of complement activation
markers correlated with disease activity and deposition of C3 and
C5b-9 have been demonstrated in endothelial cells [46, 47].
Interestingly, some patients with STEC-HUS and TTP not re-
sponding to plasmapheresis have been successfully treated with
eculizumab [48, 49]. Regarding drug-induced aHUS, it has been
shown that endothelial cells exposed to calcineurin inhibitors re-
lease microparticles that activate the AP [50]. Inflammatory con-
ditions, platelet-derived microparticles and blood coagulation
proteins induce complement activation, which in turn increments
endothelial damage andmicrovascular thrombosis [51, 52].
Prospective studies with eculizumab in primary aHUS have
shown a significant inverse correlation between the delay in the
onset of the treatment and the degree of renal function recovery
[24]. As shown in Table 7, an almost significant trend towards a
longer delay in eculizumab therapy and a significantly shorter
duration of treatment were observed among our non-responder
patients. Further studies are needed to confirm whether an ear-
lier treatment with eculizumab or a longer administration are
associated with more positive responses and a greater recovery of
renal function in patients with these secondary forms of aHUS.
Comprehensive complement molecular and genetic studies
were performed in 22 patients, but pathogenic variants were found
only in two patients (Supplementary Table). With the exception of
these two patients (#22 and #29), eculizumab was discontinued
after a median of 8 weeks, with no patients showing TMA relapses.
Tolerance to eculizumab was excellent with no important
side effects recorded. Infectious complications coincidental with
eculizumab administration in transplanted patients were attrib-
utable to immunosuppressive therapy.
Our study has the limitations inherent to its retrospective de-
sign, with a possible bias in the selection of patients and absence
of a control group not treated with eculizumab. On the other
hand, it has major strengths: the number of recruited patients is
large and the work-up tests to exclude other types of TMA was
complete, with ADAMTS-13 activity measured in all the pa-
tients and the presence of Shiga toxin ruled out in all the cases
with gastrointestinal symptoms. Furthermore, renal biopsies
and comprehensive genetic and molecular studies were per-
formed in most patients. All the patients received the specific
treatment for their aHUS aetiology and plasmapheresis was per-
formed in most of them before eculizumab treatment.
Our findings are consistent with the observation that both
primary aHUS, associated with genetic and acquired
complement abnormalities, and secondary aHUS are character-
ized by complement dysregulation. In addition, they suggest
that while complement dysregulation is constitutive in the first
condition, it is likely temporary in the second and, therefore,
both conditions should be considered differently regarding
long-term treatment. Based on the results of this study, we sug-
gest that eculizumab could be the first-line treatment in aggres-
sive cases of secondary aHUS who do not respond to other
therapies and that a rapid administration of eculizumab would
enable an efficient recovery of renal function and complement
normalization. Prospective studies are needed to corroborate
these findings and to define the ideal duration of eculizumab
treatment in secondary aHUS.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxfordjour
nals.org.
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